Literature DB >> 6334580

IgE induces secretion of prostaglandin E2 by human monocytes.

J H Passwell, B Geiger, M Levanon, J Davidsohn, B E Cohen, B Ramot.   

Abstract

IgE was isolated from a patient with the hyper IgE, recurrent infection syndrome by immunoadsorption on sepharose bound goat anti-human IgE. Addition of this IgE to a monolayer culture of human monocytes resulted in a dose-dependent increase in PGE2 secretion. The addition of F(ab')2 fraction of goat anti-human IgE in the presence of sub-stimulating doses of IgE markedly increased PGE2 secretion; whereas addition of F(ab')2 fragment of irrelevant goat IgG had no effect. Similar activation of monocytes which could be enhanced by anti IgE was observed in the presence of the patient's serum. No such effect was seen in the presence of normal human serum. These results indicate that IgE may activate human monocytes and induce PGE secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334580      PMCID: PMC1577113     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Immunosuppression in man: suppression by macrophages can be mediated by interactions with regulatory T cells.

Authors:  J D Stobo
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections.

Authors:  H R Hill; P G Quie
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

3.  Extreme hyperimmunoglobulinemia E and undue susceptibility to infection.

Authors:  R H Buckley; B B Wray; E Z Belmaker
Journal:  Pediatrics       Date:  1972-01       Impact factor: 7.124

4.  Specificities of prostaglandins B 1 , F 1 , and F 2 antigen-antibody reactions.

Authors:  L Levine; R M Gjtierrez Cernosek; H Van Vunakis
Journal:  J Biol Chem       Date:  1971-11-25       Impact factor: 5.157

Review 5.  Mechanisms of reaginic hypersensitivity and IgE antibody response.

Authors:  K Ishizaka; T Ishizaka
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

6.  Staphylococcal IgE antibodies, hyperimmunoglobulinemia E and Staphylococcus aureus infections.

Authors:  K Schopfer; K Baerlocher; P Price; U Krech; P G Quie; S D Douglas
Journal:  N Engl J Med       Date:  1979-04-12       Impact factor: 91.245

7.  Drugs which inhibit prostaglandin biosynthesis.

Authors:  R J Flower
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

Review 8.  Prostaglandins as mediators of inflammation.

Authors:  J R Vane
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

9.  Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

Authors:  J S Goodwin; R P Messner; G T Peake
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  4 in total

1.  Activation of human monocytes via their sIgA receptors.

Authors:  S Padeh; C L Jaffe; J H Passwell
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 2.  Fc epsilon receptor II-positive macrophages and platelets: potent effector cells in allergy and defence against helminth parasites.

Authors:  J P Dessaint; A Capron
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Depressed lymphocyte transformation and the role of prostaglandins in atopic dermatitis.

Authors:  T Jakob; B N Huspith; Y E Latchman; R Rycroft; J Brostoff
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Regulation of IgE synthesis by macrophages expressing FcE-receptors: role of interleukin 1.

Authors:  C Mazingue; V Carrière; J P Dessaint; F Detoeuf; T Turz; C Auriault; A Capron
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.